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Abstract 
Metabolic syndrome (MetS) has been found to be associated with inflammatory molecules. This study was conducted 
among 125 MetS patients at B P Koirala Institute of Health Sciences, Dharan, Nepal to find an association of high-
sensitivity C-reactive protein (hs-CRP) and serum uric acid with MetS components. Anthropometric measurements, 
blood pressure, medical history and blood samples were taken. Estimation of hs-CRP, serum uric acid, blood glucose, 
triglyceride and high density lipoprotein (HDL) cholesterol was done. hs-CRP had positive correlation with blood 
glucose (r = 0.2, p = 0.026) and negative with HDL cholesterol (r = −0.361, p < 0.001). Serum uric acid had positive 
correlation with waist circumference (r = 0.178, p = 0.047). Patients with elevated hs-CRP and uric acid had higher 
waist circumference (p = 0.03), diastolic BP (p = 0.002) and lower HDL cholesterol (p = 0.004) than others. Elevated 
hs-CRP and high uric acid were individually associated with higher odds for low HDL cholesterol (7.992; 1.785–35.774, 
p = 0.002) and hyperglycemia (2.471; 1.111–5.495, p = 0.029) respectively. Combined rise of hs-CRP and uric acid was 
associated with severity of MetS (p < 0.001) and higher odds for hyperglycemia (8.036; 2.178–29.647, p = 0.001) as 
compared to individual rise of hs-CRP or uric acid. The present study demonstrates that hs-CRP and serum uric acid 
are associated with MetS components, and the combined rise of hs-CRP and uric acid is associated with the increase 
in severity of MetS.
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Background
Metabolic syndrome (MetS) is the clustering of sev-
eral cardiovascular risk factors leading to increased risk 
of developing cardiovascular disease (CVD) and dying 
(Paoletti et al. 2006). MetS is a major and escalating pub-
lic health and clinical challenge worldwide and is rising 
throughout the globe including developing countries like 
Nepal (Kaur 2014; O’Neill and O’Driscoll 2015; Sharma 
et  al. 2011). Thus it is important to study the factors 
responsible for rapid rise of MetS and investigate mark-
ers that can predict risk for MetS early and the risk for 
future adverse events. Since, MetS is a state of chronic 
low grade inflammation as a consequence of complex 
interplay between genetic and environmental factors, 
inflammatory molecules seem to mediate the MetS com-
ponents (Kaur 2014; Ma et  al. 2012). Measurements of 
the circulating levels of the inflammatory molecules that 
accompany this syndrome might provide therapeutic 
approaches to modulate the inflammatory responses and 
thereby alter disease progression (Ma et al. 2012).
High-sensitivity C-reactive protein (hs-CRP) has been 
found to be associated with MetS. Hs-CRP is highly pre-
dictive of subsequent risk of cardiovascular events and dia-
betes mellitus in apparently healthy men and women (den 
Engelsen et al. 2012). Though, hs-CRP may serve as early 
marker for CVD and MetS, there is less evidence about 
relationship between hs-CRP level and the severity of MetS 
(as quantified by the increasing concurrence of individual 
MetS components; 3, 4 or 5), and there are evidences that 
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addition of hs-CRP to the present definition of the MetS 
may help identify patients at high risk for future diabetes 
and CVD (Devaraj et  al. 2009). Elevated serum uric acid 
level has been seen in MetS, and there appears to be link 
between MetS and serum uric acid (Serpa Neto et al. 2011). 
Hyperuricemia predicts the development of hypertension, 
obesity, and type 2 diabetes mellitus. Thus, uric acid may 
not only acts as surrogate marker of MetS, but also have a 
pathogenic role in the development of MetS, and therapies 
that lower uric acid may improve certain components of 
MetS (Billiet et  al. 2014). Though an association between 
hyperuricemia and hs-CRP has been observed, the com-
bined effect of hs-CRP and uric acid increase on MetS 
components is inadequately defined (Kawamoto et  al. 
2013). Thus it seems important to assess combined effects 
due to hs-CRP and uric acid rise on MetS parameters and 
to find if combined rise of hs-CRP and uric acid may have 
more severe effects on MetS than their individual rise.
Ethnicity has been suggested as a major factor in deter-
mining expression level of various metabolic markers and 
their association with CVD, type 2 diabetes and MetS 
(Abu-Farha et al. 2014). Studies investigating hs-CRP and 
uric acid in MetS are lacking in Nepalese population, and 
the clinical importance of measuring such markers has 
not been studied in Nepalese population. In the light of 
this gap in evidence from our settings and the undefined 
relationships between combined effects of h-CRP and 
uric acid rise on MetS components, we conducted a study 
among Nepalese MetS patients to explore the relationship 
between hs-CRP, serum uric acid and MetS components. 
The study also aims to evaluate the effect of the combined 
rise of hs-CRP and uric acid on MetS components.
Methods
It was a cross-sectional study involving 125 MetS 
patients recruited at Department of Biochemistry of B 
P Koirala Institute of Health Sciences, Nepal. The aim 
was to find an association between hs-CRP, serum uric 
acid and MetS components, and to determine whether 
combined increase of hs-CRP and serum uric acid is 
associated with MetS components. The study patients 
were recruited from the B P Koirala Institute of Health 
Sciences conveniently using the study inclusion criteria. 
Following informed consent, blood pressure (BP) were 
measured using standard methods and 5  ml of fasting 
blood samples were collected from the patients whose 
waist circumference were ≥90  cm in men and ≥80  cm 
in women. Only patients fulfilling International Diabe-
tes Federation (IDF) criteria for MetS were enrolled in 
the study. According to this criteria; for a person to be 
defined as having the MetS they must have; central obe-
sity (defined as waist circumference with ethnicity spe-
cific values, for South Asians: waist circumference ≥90 
Cm for males and ≥80 Cm for females), plus any two of 
the following four factors: triglycerides ≥150 mg/dL or 
on treatment for lowering this lipid, high density lipopro-
tein (HDL) cholesterol <40 mg/dL in men or <50 mg/dL 
in women or on treatment for HDL cholesterol, systolic 
BP ≥130 mm Hg or diastolic BP ≥85 mm Hg or on treat-
ment for hypertension, fasting blood glucose ≥100 mg/
dL or on treatment for type 2 diabetes (Kaur 2014). 
Raised BP or hypertension, raised glucose or hyperglyce-
mia, hypertriglyceridemia and low HDL was considered 
if the subject’s systolic BP ≥130 mm Hg or diastolic BP 
≥85 mm Hg, fasting blood glucose ≥100 mg/dL, triglyc-
erides ≥150 mg/dL and HDL cholesterol <40 mg/dL in 
men or <50 mg/dL in women respectively (Kaur 2014). 
Exclusion criteria of the participants include: presence 
of acute infections and chronic inflammatory diseases, 
gout patients. After defining MetS, each patient demo-
graphic characteristics (age, sex), height, weight, medical 
history of diabetes mellitus and hypertension were noted. 
The study protocol was approved by the institute review 
board of B P Koirala Institute of Health Sciences.
Serums from overnight fasting blood samples were 
stored at −20  °C until analysis. Blood glucose was esti-
mated using enzymatic method. Serum triglyceride was 
measured by enzymatic method (kits from AGAPPE 
diagnostics). High density lipoprotein (HDL) cholesterol 
was estimated by homogeneous, direct method using 
kit from Gesan by Biolyzer 100, and hs-CRP was meas-
ured by enzyme immunoassay using kit from diagnostics 
biochem canada (DBC) and the reading was taken using 
LabLife ER 2007 plate reader. Uric acid was measured by 
uricase peroxidase method. We dichotomized hs-CRP 
(hs-CRP <1  mg/L as non-elevated hs-CRP and low risk 
group, and hs-CRP ≥1 mg/L as elevated hs-CRP and high 
risk group) and serum uric acid (serum uric acid <6 mg/
dL as normal uric acid group and serum uric acid ≥6 mg/
dL as hyperuricemia group) and analyzed MetS compo-
nents in each group. We used hs-CRP <1 or ≥1 mg/L and 
serum uric acid <6 or ≥6 mg/dL as a cutoff. Usually, hs-
CRP ≥ 1 mg/L, indicates intermediate or high cardiovas-
cular risk, whereas, hs-CRP <1 mg/L is considered a low 
cardiovascular risk (den Engelsen et  al. 2012). We took 
uric acid ≥6 mg/dL as high uric acid/hyperuricemia since 
exact cutoff of serum uric acid for hyperuricemia in Nep-
alese population has not been established, and uric acid 
level even at upper normal range could bring risk for hav-
ing MetS components, and some define hyperuricemia 
as uric acid >6  mg/dL (women) and >6.8  mg/dL (men) 
(Billiet et al. 2014; Serpa Neto et al. 2011). Similarly, we 
compared MetS components among 4 groups made by 
considering both hs-CRP and serum uric acid; group one 
with hs-CRP < 1 mg/L and normal uric acid, group two 
with hs-CRP  <  1  mg/L and hyperuricemia, group three 
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with hs-CRP ≥ 1 mg/L and normal uric acid and group 
four with hs-CRP ≥ 1 mg/L and hyperuricemia.
The data were analyzed using SPSS version 20. The 
continuous variables were expressed as mean ±  SD for 
variables showing normal distribution, and as median 
with interquartile rage for variables showing non-nor-
mal distribution. Categorical variables are expressed as 
number (percentage). Correlations between hs-CRP and 
MetS components were calculated using Spearman rank 
correlation analysis, and between serum uric acid level 
and MetS components using Pearson’s correlation analy-
sis at 95 % confidence interval. Correlation between hs-
CRP and uric acid level was measured using Spearman 
rank correlation analysis at 95  % confidence interval. 
Independent t test, one way ANOVA, Man Whitney test 
and Kruskal–Wallis test were applied at 95 % confidence 
interval to test for the significance. The odds ratio with 
95 % CI was estimated to find risk for having hyperten-
sion, hyperglycemia, hypertriglyceridemia and low HDL 
in patients with elevated hs-CRP, hyperuricemia or both 
as compared to those with low hs-CRP, uric acid or both 
respectively. A p value less than 0.05 was considered as 
statistically significant at 95 % confidence interval.
Results
The mean age of the study population was 
47.5  ±  11.1  years (age range 22–73  years). Males and 
females were 44  % (n =  55) and 56  % (n =  70) respec-
tively. History of diabetes mellitus and hypertension was 
present in 55.2  % (n  =  69) and 76  % (n  =  95) respec-
tively. Mean height, weight and BMI of study population 
were 158.5 ±  8.2 Cm, 70.1 ±  9.6 kg and 27.9 ±  3.4 kg/
m2 respectively. The mean level of MetS components; 
waist circumference, systolic BP, diastolic BP, fasting 
blood glucose, triglyceride and HDL cholesterol were 
103.8 ± 7.4 Cm, 128.8 ± 13.3 mmHg, 84.1 ± 10.6 mmHg, 
128.9  ±  48.9  mg/dL, 208.2  ±  80.7  mg/dL and 
50.3  ±  13.2  mg/dL respectively. The median hs-CRP 
and mean serum uric acid level was 2.5  mg/L (1  mg/L; 
5.1  mg/L) and 6.6  ±  1.8  mg/dL respectively. No 
significant difference in MetS components was observed 
among male and female patients except for waist circum-
ference (male 106 ± 5.4 Cm and female 102.1 ± 8.4 Cm; 
p = 0.003) and HDL cholesterol (male 47.2 ± 11.9 mg/dL 
and female 52.7 ± 13.6 mg/dL, p = 0.018). MetS compo-
nents according to level of hs-CRP and uric acid is shown 
in Table  1. Significant difference in MetS components; 
systolic BP (p  =  0.043), diastolic BP (p  =  0.005) and 
HDL cholesterol (p < 0.001) was observed among patient 
with hs-CRP < 1 mg/L and hs-CRP ≥ 1 mg/L. However, 
only significant difference (p  =  0.009) in MetS compo-
nent; waist circumference was observed among patients 
with normal uric acid and hyperuricemic patients. MetS 
components in the 4 groups made by considering level 
of hs-CRP and uric acid is shown in Table 2. There was 
significant rise in waist circumference and diastolic BP 
and significant decrease in HDL cholesterol across the 
groups. 
The correlation of hs-CRP with MetS components; 
waist circumference, systolic BP, diastolic BP, fasting 
blood glucose, triglyceride and HDL cholesterol were 
0.15 (p = 0.095), −0.008 (p = 0.931), 0.072 (p = 0.426), 
0.2 (p = 0.026), 0.124 (p = 0.168) and −0.361 (p < 0.001) 
respectively. The correlation of serum uric acid with waist 
circumference, systolic BP, diastolic BP, fasting blood 
glucose, triglyceride and HDL cholesterol were 0.178 
(p =  0.047), 0.099 (p =  0.271), 0.121 (p =  0.181), 0.144 
(p =  0.109), 0.095 (p =  0.294) and −0.034 (p =  0.704). 
Significant correlation (r = 0.19, p = 0.034) was observed 
between hs-CRP and serum uric acid level.
Among the study population 3, 4 and 5 components 
of MetS was present in 66, 37 and 22 patients respec-
tively. All 5 components were very common in patients 
(19 patients out of 22) with elevated hs-CRP and hyper-
uricemia than compared to 4 (15 patients out of 37) 
and 3 (25 patients out of 66) components. Combined 
rise of hs-CRP and uric acid was associated with sever-
ity of MetS (p  <  0.001). Median hs-CRP and mean uric 
acid level in patients with 3, 4 and 5 components were 
1.1  mg/L (1; 4) and 6.3  ±  1.7  mg/dL, 3.2  mg/L (1.6; 
Table 1 MetS components according to hs-CRP and uric acid level
The data is expressed as mean ± SD
MetS metabolic syndrome, hs-CRP high sensitivity C reactive protein, HDL high density lipoprotein




P value Uric acid <6 mg/dL, 
N = 55
Uric acid ≥6 mg/dL, 
N = 70
P value
Waist circumference (Cm) 101.8 ± 6.3 104.3 ± 7.6 0.14 101.9 ± 6.2 105.3 ± 8 0.009
Systolic BP (mmHg) 124 ± 13.2 130 ± 13.1 0.043 127.5 ± 14.5 129.9 ± 12.3 0.318
Diastolic BP (mmHg) 78.8 ± 11.2 85.5 ± 10.1 0.005 82.5 ± 10.6 85.4 ± 10.5 0.121
Fasting blood glucose (mg/dL) 114.4 ± 41.7 132.5 ± 50.1 0.097 121.1 ± 50.3 135.1 ± 47.2 0.113
Triglyceride (mg/dL) 188.7 ± 55.7 213.1 ± 85.3 0.087 210.4 ± 89.9 206.6 ± 73.2 0.795
HDL cholesterol (mg/dL) 58.6 ± 12 48.2 ± 12.6 <0.001 50.9 ± 12.9 49.8 ± 13.4 0.648
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5.6) and 6.5  ±  1.7  mg/dL, and 4.4  mg/L (2.1; 8.1) and 
7.8  ±  1.8  mg/dL respectively. Hs-CRP (p  <  0.001) and 
uric acid level (p  =  0.005) were significantly different 
among those with 3, 4 and 5 components.
Among the study patients, hypertension, hyperglyce-
mia, hypertriglyceridemia and low HDL cholesterol were 
observed in 76 % (n = 95), 72 % (n = 90), 80 % (n = 100) 
and 34.4 % (n = 43) patients respectively. The prevalence 
rate of raised BP, hyperglycemia and low HDL choles-
terol was higher in group with hs-CRP  ≥  1  mg/L than 
hs-CRP < 1 mg/L, and in hyperuricemia group than nor-
mal uric acid group. However, hypertriglyceridemia rate 
remained similar across the group. Odds ratio of having 
hypertension, hyperglycemia, hypertriglyceridemia and 
low HDL cholesterol in patients with elevated hs-CRP 
as compared to those with non-elevated hs-CRP, and 
in patients with hyperuricemia as compared to those 
with normal uric acid level is shown in Table 3. Signifi-
cant odds of having low HDL cholesterol were observed 
in patients with elevated hs-CRP as compared to those 
with non-elevated hs-CRP. Hyperuricemic patients have 
significant odds of having hyperglycemia as compared 
to patients with normal uric acid level. The odds ratio 
of having hypertension, hyperglycemia, hypertriglyceri-
demia and low HDL cholesterol in patients with non-ele-
vated hs-CRP and hyperuricemia, elevated hs-CRP and 
normal uric acid, and elevated hs-CRP and hyperurice-
mia as compared to the patients with non-elevated hs-
CRP and normal uric acid is shown in Table 3. Patients 
with elevated hs-CRP and normal uric acid, and with 
elevated hs-CRP and hyperuricemia had significant odds 
of having hyperglycemia as compared to those with low 
hs-CRP and normal uric acid.
Discussion
South Asians are more prone to develop MetS because of 
their high percentage of body fat, abdominal obesity, and 
insulin resistance (Mahalle et  al. 2014). Hypertension, 
MetS and diabetes mellitus has been rising in Nepalese 
population. Accompanying with the rise of chronic dis-
eases like diabetes mellitus, MetS and chronic kidney 
diseases, there is increase in endocrine disorders like 
thyroid dysfunction, dyslipidemia and CVD in Nepal 
(Khatiwada et al. 2015a, b, 2016; Sharma et al. 2011). The 
present study was conducted among MetS patients in 
eastern Nepal. All of the study patients were obese (waist 
circumference 103.8 ± 7.4 Cm). The mean level of MetS 
components was similar to our previous study among 
MetS patients in eastern Nepal (Khatiwada et  al. 2016). 
Among the gender, females had significantly lower waist 
circumference and HDL cholesterol than male patients. 
Epidemiological research has shown that there is gender 
disparity among these components of MetS. In a study 
in Pakistan, similar finding among gender was reported 
(Jahan et al. 2007).
The median hs-CRP level (2.5 mg/L) in our study popu-
lation was in risk zone and similar to the values seen in 
earlier studies. In a study in India, median levels of hs-
CRP were considerably higher in individuals with MetS 
(Mahajan et al. 2012). In study by Engelsen et al., median 
hs-CRP levels were significantly higher in individuals 
with central obesity with the MetS compared to individu-
als with central obesity without the metabolic syndrome 
(2.2 versus 1.7  mg/L, p  <  0.001) (den Engelsen et  al. 
2012). In the present study, we observed that median hs-
CRP level increases significantly with increasing num-
ber of MetS components. Thus, patients with all 5 MetS 
components have higher hs-CRP than those with 4 and 
3 components. This finding is similar to that reported 
by Nishida et  al., who reported that individuals with an 
increased number of MetS components have higher CRP 
levels, and by Yan et  al., who demonstrated increase in 
hs-CRP among Uyghurs and Kazakhs as the cluster-
ing of MetS components increased (Yan et al. 2015). We 
observed significant positive correlation between hs-
CRP and fasting blood glucose, and significant negative 
Table 2 MetS components according to combined hs-CRP and uric acid level
The data is expressed as mean ± SD
MetS metabolic syndrome, hs-CRP high sensitivity C reactive protein, HDL high density lipoprotein
MetS components Non-elevated hs-CRP  
and uric acid <6 mg/dL,  
n = 14
Non-elevated hs-CRP  
and uric acid ≥6 mg/dL,  
N = 11
Elevated hs-CRP  
and uric acid <6 mg/dL,  
n = 41
Elevated hs-CRP  
and uric acid ≥6 mg/dL,  
n = 59
P value
Waist circumference (Cm) 101.4 ± 5.9 102.4 ± 7 102 ± 6.3 105.9 ± 8.1 0.03
Systolic BP (mmHg) 123.9 ± 14.6 124.1 ± 12 128.7 ± 14.4 130.9 ± 12.2 0.19
Diastolic BP (mmHg) 81.4 ± 12.2 75.5 ± 9.3 82.8 ± 10.2 87.3 ± 9.7 0.002
Fasting blood glucose (mg/
dL)
98.6 ± 44.5 134.5 ± 28.4 128.8 ± 50.4 135.2 ± 50.1 0.089
Triglyceride (mg/dL) 198.9 ± 53.5 175.6 ± 58.2 214.3 ± 99.6 212.3 ± 74.7 0.505
HDL cholesterol (mg/dL) 58.6 ± 14.7 58.7 ± 8 48.2 ± 11.2 48.1 ± 13.6 0.004
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correlation of hs-CRP with HDL cholesterol. A num-
ber of studies have observed an association of hs-CRP 
with various MetS components (Abu-Farha et  al. 2014; 
DeBoer et al. 2011; den Engelsen et al. 2012). In study in 
non–Hispanic black adolescents in US, with the excep-
tion of diastolic BP and fasting glucose, hs-CRP was 
significantly correlated with each of the components of 
MetS, however in a study among Arab population signifi-
cant correlation of hs-CRP was observed with all compo-
nents of MetS (Abu-Farha et al. 2014; DeBoer et al. 2011).
In our study cohort, we observed significantly higher 
BP (systolic and diastolic) and lower HDL cholesterol, 
and increasing prevalence of hypertension, hyperglyce-
mia and low HDL cholesterol with the rise in hs-CRP. 
Similarly, patients with elevated hs-CRP showed higher 
risk for hypertension, hyperglycemia and low HDL 
cholesterol as compared to patients with non-elevated 
hs-CRP. Similar trends were observed in the study by 
Yan et  al., where prevalence of MetS and its compo-
nents increased across the quartiles of hs-CRP level, 
and risk for MetS and its components were higher for 
fourth quartile as compared to first quartile of hs-CRP 
(Yan et  al. 2015). Another study by Kawamoto et  al., 
also observed that prevalence rate of MetS and its com-
ponents increased significantly in relation to the higher 
tertiles of hs-CRP, and odds ratios of hs-CRP were signif-
icantly high for obesity, hypertriglyceridemia, low HDL 
cholesterolemia and impaired fasting glucose (Kawamoto 
et al. 2013). The mechanisms by which hs-CRP reflect the 
risk for MetS are not completely understood. However, 
systemic inflammation is closely involved in the patho-
genesis of MetS, and thus, elevated hs-CRP may also 
reflect inflammation, which impairs insulin signaling in 
the liver, muscle, and adipose tissues, and influence insu-
lin resistance, lipid and glucose metabolism (Kawamoto 
et  al. 2013). Further investigations are required to find 
the molecular role of CRP in the pathogenesis of MetS.
The mean serum uric acid (6.9 ±  1.6  mg/dL for male 
and 6.4 ± 1.9 mg/dL for female) in our study population 
was higher than the normal range for males and females. 
Previous studies have also reported higher serum uric 
acid level in MetS patients than compared to non-MetS 
patients (Nejatinamini et al. 2015; Numata et al. 2008). In 
the current study, we found significantly higher waist cir-
cumference in patients with hyperuricemia as compared 
to patients with normal uric acid level and a significant 
positive correlation of serum uric acid with waist circum-
ference. Study by Nejatinamini et al. (2015) and Li et al. 
(2011) have found strong correlation between serum uric 
acid and MetS components.
Our findings show that serum uric acid level increases 
with increase in severity of MetS, and prevalence of 
hypertension, hyperglycemia and low HDL cholesterol 
increases with the rise in serum uric acid. Also, hyper-
uricemic patients have higher odds of having hyper-
tension, hyperglycemia and low HDL cholesterol as 
compared to patients with normal serum uric acid level. 
A number of previous studies have reported such find-
ings (Lin et al. 2006; Liu et al. 2014). In the study by Lin 
et al., serum uric acid level was elevated significantly as 
the number of metabolic components increased (Lin 
et al. 2006). In a study in China, the prevalence of MetS 
increased with rise in serum uric acid and MetS compo-
nent number showed an increasing trend across serum 
uric acid quartile in both sexes (p for trend < 0.01). Simi-
larly, participants with hyperuricemia or higher serum 
uric acid level were at significantly elevated odd ratios 
for MetS and most of its five individual components (Liu 
et  al. 2014). While it has been suggested that uric acid 
may simply be a consequence of the increased uric acid 
absorption in the proximal tubule secondary to hyper-
insulinemia, there is growing data that uric acid may 
predict the development of MetS, obesity and diabetes. 
Although a strong relationship between hyperuricemia 
and metabolic syndrome has been established through 
animal and epidemiological studies, the potential patho-
physiological mechanisms by which uric acid contributes 
to this disease state is not clear (Soltani et al. 2013).
In the present study, we reported that combined rise 
of hs-CRP and uric acid is associated with significant 
increase in level of MetS components (waist circumfer-
ence and diastolic BP) and significant decrease in HDL 
cholesterol than individual rise of either hs-CRP or uric 
acid, and the prevalence and risk for hypertension, hyper-
glycemia and low HDL cholesterol is higher in patients 
with combined rise of hs-CRP and uric acid than in 
patients with either raised hs-CRP or uric acid. Also, the 
severity of MetS tends to be higher in patients with raised 
hs-CRP and raised uric acid than in patients with raised 
hs-CRP or uric acid, and the combined rise of hs-CRP 
and serum uric acid occurs more frequently in patients 
with higher number of MetS components. These find-
ings are in accord to a previous study by Kawamoto et al., 
who found that the odds ratio of an increased tertile of 
uric acid and hs-CRP was a significant and independent 
determinant for MetS and insulin resistance. In addition 
to their direct associations, they also observed a synergis-
tic effect between uric acid and hs-CRP (Kawamoto et al. 
2013). Since, we observed strong association of hs-CRP 
with serum uric acid level in the present study, which is 
similar to findings of Kawamoto et  al., where uric acid 
levels significantly increased with hs-CRP (r  =  0.285, 
p < 0.001), it may be possible that hs-CRP and uric acid 
act synergistically to increase severity of MetS and risk 
for further complications like diabetes mellitus and CVD 
(Kawamoto et  al. 2013). Hyperuricemia has been found 
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associated with elevated CRP and other inflammatory 
markers and there might be link between uric acid and 
hs-CRP (Krishnan 2014). In a study in China, hs-CRP 
was correlated with uric acid, and there was significant 
rise in prevalence of hyperuricemia with rise of hs-CRP 
(Sun et al. 2015).
To our knowledge, we report the association of hs-CRP 
and serum uric acid with MetS components for the first 
time in Nepalese population. Both hs-CRP and uric acid 
can act as an indicator of inflammation, which may nega-
tively affect the MetS components thereby increasing 
CVD risk. Our previous study in eastern Nepal reported 
higher preponderance of CVD risk factors in subclini-
cal hypothyroidism patients who had high hs-CRP lev-
els than control having low hs-CRP (Kc et al. 2015). Our 
findings suggest that measurement of hs-CRP and uric 
acid may be helpful to assess severity of MetS. Because 
of the elevated hs-CRP in MetS patients and its ability to 
predict future adverse outcomes such as diabetes mellitus 
and CVD in MetS, adding hs-CRP as a clinical criterion 
for MetS may be advantageous (Devaraj et al. 2009).
The present study has some limitations, which should 
be considered. First, the study sample size was small, thus 
there might be effects on generalization of our findings. 
Since, this was a cross-sectional study one cannot overtly 
draw conclusion about the casual relationships between 
hs-CRP, uric acid and MetS components. Also, we did 
not studied hs-CRP and uric acid in subjects without any 
MetS components.
Conclusion
Our study finds an association of hs-CRP and serum 
uric acid with MetS components, though serum uric 
acid seems to be associated with fewer MetS compo-
nents than hs-CRP. Rise of hs-CRP, uric acid, or both 
tends to associated with increased risk for hypertension, 
hyperglycemia and low HDL cholesterol. Similarly, com-
bined rise of hs-CRP and uric acid is associated with the 
increase in severity of MetS. Thus, hs-CRP and uric acid 
may be used to assess severity of MetS.
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